Cargando…

Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment‐naive patients with advanced EGFR mutation‐positive non‐small cell lung cancer: Protocol of an open‐label, single‐arm phase II trial

INTRODUCTION: Non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation has a higher incidence of brain metastases than wild‐type EGFR mutations. Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor (TKI), targets both EGFR‐TKI sensitizing and T790M‐resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Bora, Ji, Wonjun, Lee, Jae Cheol, Song, Si Yeol, Shin, Young Seob, Cho, Young Hyun, Park, Ji Eun, Park, Hyungjun, Choi, Chang‐Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396779/ https://www.ncbi.nlm.nih.gov/pubmed/37365915 http://dx.doi.org/10.1111/1759-7714.15018

Ejemplares similares

Lazertinib: on the Way to Its Throne
por: Lee, Jiyun, et al.
Publicado: (2022)

Lazertinib: First Approval
por: Dhillon, Sohita
Publicado: (2021)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

Correction to: Lazertinib: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies
por: Jang, Seong Bok, et al.
Publicado: (2021)

Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2023)

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
por: Cho, Byoung Chul, et al.
Publicado: (2023)

Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
por: Kim, Bomin, et al.
Publicado: (2022)

Nivolumab as maintenance therapy following platinum‐based chemotherapy in EGFR ‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial
por: Kim, Jiwon, et al.
Publicado: (2023)

A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation‐positive non‐small cell lung cancer (stage III) who have not progressed following definitive, platinum‐based, chemoradiation therapy (PLATINUM trial)
por: Choi, Juwhan, et al.
Publicado: (2022)

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
por: Peled, Nir, et al.
Publicado: (2021)

EV-based EGFR genotyping in bronchoalveolar lavage fluid—a step forward from blood?
por: Ji, Wonjun, et al.
Publicado: (2020)

Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review
por: Fang, Yue, et al.
Publicado: (2023)

Magnetic resonance imaging of posterolateral plica of the elbow joint: Asymptomatic vs. symptomatic subjects
por: Choi, Sang-Hee, et al.
Publicado: (2017)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study)
por: Sawada, Ryo, et al.
Publicado: (2023)

P1042: COMPARISON OF THE RESPONSE TO ROPEGINTERFERON ALFA-2B IN HYDROXYUREA NAÏVE VERSUS RESISTANCE/INTOLERANCE POLYCYTHEMIA VERA: THE KOREAN SINGLE-ARM, OPEN-LABEL MULTICENTER STUDY
por: Lee, Sung-Eun, et al.
Publicado: (2023)

Melanoma Metastasizing to the Small Intestine: A Case Report Illustrating Symptomatic and Asymptomatic Involvement
por: Asad-Ur-Rahman, FNU, et al.
Publicado: (2016)

Two‐year efficacy of SNK01 plus pembrolizumab for non‐small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial
por: Park, Hyung Jun, et al.
Publicado: (2022)

Construction of a non-contact community treatment centre for asymptomatic and mildly symptomatic COVID-19 patients during the COVID-19 pandemic
por: Kim, Si Hyun, et al.
Publicado: (2021)

Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo
por: Fan, Yingfang, et al.
Publicado: (2022)

Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations
por: Kim, Ho Cheol, et al.
Publicado: (2019)

A comparison between asymptomatic and symptomatic ureteral stones
por: Noh, Tae Il, et al.
Publicado: (2023)

Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection
por: Choe, Pyoeng Gyun, et al.
Publicado: (2021)

Infectivity of asymptomatic versus symptomatic COVID-19
por: Sayampanathan, Andrew A, et al.
Publicado: (2021)

Asymptomatic Stenosis in the Cervical and Thoracic Spines of Patients with Symptomatic Lumbar Stenosis
por: Park, Moon Soo, et al.
Publicado: (2015)

Efficacy of nebulized acetylcysteine for relieving symptoms and reducing usage of expectorants in patients with radiation pneumonitis
por: Han, Dong‐Woo, et al.
Publicado: (2018)

Clinical Outcome of Stereotactic Body Radiotherapy in Patients with Early-Stage Lung Cancer with Ground-Glass Opacity Predominant Lesions: A Single Institution Experience
por: Jang, Jeong Yun, et al.
Publicado: (2023)

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
por: Hyun, Dong-gon, et al.
Publicado: (2020)

Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study
por: Zhou, Tie, et al.
Publicado: (2020)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
por: Park, Keunchil, et al.
Publicado: (2021)

Biomarkers expression among paired serous ovarian cancer primary lesions and their peritoneal cavity metastases in treatment‐naïve patients: A single‐center study
por: Nikas, Ilias P., et al.
Publicado: (2022)

Energy refinement and analysis of structures in the QM9 database via a highly accurate quantum chemical method
por: Kim, Hyungjun, et al.
Publicado: (2019)

Prognostic Factor and Clinical Outcome in Stage III Non–Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population
por: Kim, Ho Cheol, et al.
Publicado: (2021)

Intracranial Efficacy of Systemic Therapy in Patients with Asymptomatic Brain Metastases from Lung Cancer
por: Sun, Min-Gwan, et al.
Publicado: (2023)

Contrasting transcriptional responses to Fusarium virguliforme colonization in symptomatic and asymptomatic hosts
por: Baetsen-Young, Amy, et al.
Publicado: (2020)

Myocardial scarring on cardiovascular magnetic resonance in asymptomatic or minimally symptomatic patients with “pure” apical hypertrophic cardiomyopathy
por: Kim, Kyung-Hee, et al.
Publicado: (2012)

Risk Score Model for the Assessment of Coronary Artery Disease in Asymptomatic Patients With Type 2 Diabetes
por: Park, Gyung-Min, et al.
Publicado: (2015)

Detection of asymptomatic recurrence improves survival of gastric cancer patients
por: Park, Ji Soo, et al.
Publicado: (2021)

A Case of Asymptomatic, Localized, and Idiopathic Diffuse Alveolar Damage
por: Jeon, Young Do, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_m2eulfcon2fm1airqci94ifgpn